Glucagon inhibits insulin activation of glucose transport in rat adipocytes mainly through a postbinding process. 1990

N Sato, and M Irie, and H Kajinuma, and K Suzuki
Division of Endocrinology and Metabolism, Asahi Life Foundation, Tokyo, Japan.

Incubation of rat adipocytes with 1 microM glucagon plus adenosine deaminase (5 micrograms/ml) inhibited maximally insulin-stimulated 3-O-methyl-D-glucose (MeGlc) transport by approximately 70%, concomitant with 30% and 55% decreases in insulin binding and cellular ATP, respectively. In contrast, under conditions where cellular ATP levels are well preserved (i.e. high albumin concentration in the medium), the inhibition of transport was reduced to about 30%, but that of insulin binding was not. Because depletion of the cellular ATP level by more than 60% by metabolic inhibitors induced 40% or more inhibition of insulin-stimulated MeGlc transport, the greater inhibition of the transport with the low albumin concentration appears to be caused in part by the secondary effect of ATP loss. The relationship between the amount of cell-bound insulin and hormone-stimulated transport activity showed that glucagon does not modulate insulin action at the step of insulin binding to its receptors. Furthermore, glucagon suppressed insulin-stimulated MeGlc transport, mainly through an attenuation of the hormone-induced increase in maximum velocity. The data show that glucagon modulates the process of signal transduction of insulin action. However, the possibility that glucagon directly modulates the process of translocation or the intrinsic activity of the glucose transporters cannot be eliminated.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008757 Methylglucosides Methylglucopyranosides
D008759 Methylglycosides
D011190 Potassium Cyanide A highly poisonous compound that is an inhibitor of many metabolic processes, but has been shown to be an especially potent inhibitor of heme enzymes and hemeproteins. It is used in many industrial processes. Potassium Cyanide (K(14)CN),Potassium Cyanide (K(C(15)N)),Cyanide, Potassium
D011773 Pyruvates Derivatives of PYRUVIC ACID, including its salts and esters.
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D004140 Dinitrophenols Organic compounds that contain two nitro groups attached to a phenol.
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor

Related Publications

N Sato, and M Irie, and H Kajinuma, and K Suzuki
March 1992, Diabetes research and clinical practice,
N Sato, and M Irie, and H Kajinuma, and K Suzuki
December 1985, The American journal of physiology,
N Sato, and M Irie, and H Kajinuma, and K Suzuki
December 1998, Metabolism: clinical and experimental,
N Sato, and M Irie, and H Kajinuma, and K Suzuki
September 1994, The Journal of biological chemistry,
N Sato, and M Irie, and H Kajinuma, and K Suzuki
January 2002, Journal of cellular biochemistry,
N Sato, and M Irie, and H Kajinuma, and K Suzuki
April 1978, The Journal of biological chemistry,
N Sato, and M Irie, and H Kajinuma, and K Suzuki
January 1988, FEBS letters,
N Sato, and M Irie, and H Kajinuma, and K Suzuki
December 1983, The Biochemical journal,
N Sato, and M Irie, and H Kajinuma, and K Suzuki
July 1994, Biochemical and biophysical research communications,
Copied contents to your clipboard!